Breakthrough Cancer Research invites EOIs for translational/applied cancer research with clear patient impact. Projects must target brain, liver, stomach, lung, ovarian, or early-onset colorectal cancer and demonstrate meaningful Public & Patient Involvement (PPI) and systematic evidence of need.
Eligibility Criteria:
-
Align with Breakthrough’s mission and show high potential to move into practice/clinical studies.
-
Research types may include early detection (lab, bioinformatics, AI, big data), drug validation in pre-clinical animal models, pre-clinical studies leading to phase I trials.
-
Must include active PPI and justify unmet need.
-
Only the listed cancer sites are in scope for this call.
Funding Details:
-
Up to EUR 300,000 for 12–36 months.
Deadline:
-
EOI due to [email protected] by Friday, 15 August 2025, 13:00 Irish time (EOI applications opened 21 July 2025).
-
Shortlisted full applications via HRB GEMS: 1 Sept – 15 Oct 2025 (deadline 17:00 Irish time).
-
Reviews: 15 Oct 2025 – 30 Jan 2026; Applicant response: 2–14 Feb 2026; Endorsement: 6 Mar 2026; HRB panel: late May 2026; Notification: June 2026; Project start: 3 Nov 2026 – 1 Jan 2027.
Where to Go for Further Information: